ReviewSignal transduction and targeted therapy2026
Heterogeneity in cancer: molecular mechanisms and therapeutic strategies.
Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer heterogeneity drives therapeutic failure, resistance, and relapse and encompasses variation across genetic, cellular, tissue, organ, and systemic scales. Existing frameworks define malignant capabilities and tumor-microenvironment interactions but less explicitly address how heterogeneity propagates across scales and informs therapeutic design. Here, we propose the Holistic Integrative Tumor Ecosystem Theory (HITET), a five-dimensional framework connecting these scales through functional interfaces. Its organizing principle is the niche-flow-feedback triad: niches define selective habitats; flows transmit cells, resources, and signals across scales; and feedback loops amplify or constrain heterogeneity by reshaping niches and flows. HITET generates several provisional predictions: interventions targeting three or more active dimensions may produce more durable responses than narrower strategies; tumors with strong vascular-immune coupling may be particularly sensitive to combined vascular normalization and immune activation; and clonal or phenotypic diversification may correlate with the number and strength of positive feedback loops. We use HITET to synthesize how genetic alterations, cellular plasticity, metabolic programs, immune and stromal interactions, spatial gradients, organ-specific environments, microbiota, and host physiology jointly shape cancer heterogeneity. Therapeutically, HITET organizes strategies as vertical integration within a dimension, horizontal integration across dimensions, and modulation of host-tumor interfaces. HITET does not replace existing cancer frameworks or constitute a validated predictive model. Its current contribution is organizational and hypothesis-generating, providing a structured basis for linking mechanisms and measurements and developing predictions that require prospective experimental and clinical validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.